[1]李雨芹,刘 梅.石杉碱甲联合尼莫地平治疗血管性痴呆疗效与安全性的Meta分析[J].医学信息,2020,33(11):82-85,94.[doi:10.3969/j.issn.1006-1959.2020.11.024]
　LI Yu-qin,LIU Mei.Meta Analysis of the Efficacy and Safety of Huperzine A Combined with Nimodipine in the Treatment of Vascular Dementia[J].Medical Information,2020,33(11):82-85,94.[doi:10.3969/j.issn.1006-1959.2020.11.024]
点击复制

石杉碱甲联合尼莫地平治疗血管性痴呆疗效与安全性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年11期
页码:
82-85,94
栏目:
综述
出版日期:
2020-06-01

文章信息/Info

Title:
Meta Analysis of the Efficacy and Safety of Huperzine A Combined with Nimodipine in the Treatment of Vascular Dementia
文章编号:
1006-1959（2020）11-0082-05
作者:
李雨芹; 刘 梅
（四川省成都市第六人民医院神经内科，四川 成都 610051）
Author(s):
LI Yu-qin; LIU Mei
(Department of Neurology,the Sixth People’s Hospital of Chengdu,Chengdu 610051,Sichuan,China)
关键词:
石杉碱甲; 尼莫地平; 血管性痴呆
Keywords:
Huperzine A; Nimodipine; Vascular dementia
分类号:
R287
DOI:
10.3969/j.issn.1006-1959.2020.11.024
文献标志码:
A
摘要:
目的 探讨石杉碱甲联合尼莫地平治疗血管性痴呆的临床疗效与安全性。方法 检索PubMed、中国学术网期刊全文数据库、中国维普数据库、万方数据库1990~2019年公开发表的关于石杉碱甲联合尼莫地平治疗血管性痴呆的临床随机对照试验的相关文献，符合标准的应用Review Manager5.3软件进行Meta分析。结果 纳入的9个临床研究，844例患者。Meta分析显示，治疗组简易精神状态智能量表（MMSE）评分、改良长谷川简易智能量表（HDS-R）评分、日常生活活动能力量表（ADL）评分优于对照组（P＜0.00001）；治疗组不良反应发生率高于对照组，差异有统计学意义（P=0.04），但不良反应症状轻，不影响继续给药治疗。结论 石杉碱甲与尼莫地平的联合治疗在血管性痴呆有助于改善患者的认知功能和生活自理能力，不良反应轻，不影响治疗效果，联合治疗较安全。
Abstract:
Objective To explore the clinical efficacy and safety of huperzine A combined with nimodipine in the treatment of vascular dementia. Methods Search PubMed, China Academic Journal Full-text Database, China Weipu Database, Wanfang Database was the relevant literature published in the clinical randomized controlled trial of Huperzine A combined with nimodipine in the treatment of vascular dementia published in 1990~2019, and met the standard of the application of Review Manager5.3 software for Meta analysis.Results 9 clinical studies included, 844 patients. Meta analysis showed that the treatment group’s simple mental state intelligence scale (MMSE) score, modified Hasegawa simple intelligence scale (HDS-R) score, and daily life activity scale (ADL) score were better than the control group (P＜0.00001) ; The incidence of adverse reactions in the treatment group was higher than that in the control group, the difference was statistically significant (P=0.04), but the symptoms of adverse reactions were mild and did not affect the continued administration of the drug.Conclusion The combined treatment of Huperzine A and Nimodipine can help patients with vascular dementia to improve their cognitive function and ability to take care of themselves. The side effects are mild, the treatment effect is not affected, combination therapy is safe.

参考文献/References:

[1]胡风丽,谢家骏,王茜,等.石杉碱甲治疗血管性痴呆的有效性与安全性Meta分析[J].中成药,2018,42(5):1222-1226.[2]张雪珍.尼莫地平治疗中轻度血管性痴呆患者的疗效分析及对认知功能和日常生活能力的影响[J].北方药学,2018,15(1):48-49.[3]郝敏峰,任秀,吴中亮.尼莫地平联合吡拉西坦治疗脑梗死后血管性痴呆的Meta分析[J].中国医药导报,2016,13(20):140-144.[4]步霄,贾师捷,梁梦飞,等.石杉碱甲联合尼莫地平对脑梗死血管性痴呆患者认知功能以及日常生活能力的影响[J].黑龙江医学,2018,42(6):582-583.[5]张彩霞,余晓峰.石杉碱甲及尼莫地平联合多奈哌齐治疗轻中度老年血管性痴呆的疗效[J].中国老年学杂志,2015(12):3298-3299.[6]高亚军,屈永才,薛艺东.石杉碱甲与尼莫地平治疗轻中度血管性痴呆的疗效及安全性[J].实用临床医药杂志,2015,19(7):121-122.[7]张旭君.石杉碱甲与尼莫地平治疗轻中度血管性痴呆的疗效及安全性[J].中国实用神经疾病杂志,2012,15(21):76-78.[8]程小秧.石杉碱甲联合尼莫地平治疗血管性痴呆80例[J].浙江中西医结合杂志,2012,22(8):610-611.[9]徐猛.石杉碱甲联合尼莫地平治疗轻中度血管性痴呆的疗效观察[J].中国实用神经疾病杂志,2012,15(20):15-17.[10]王群松,于海燕.石杉碱甲联合尼莫地平治疗血管性痴呆的对照观察[J].中国健康心理学杂志,2011(2):154-155.[11]范伟女.石杉碱甲联合尼莫地平治疗轻中度血管性痴呆的临床观察[J].心脑血管病防治,2009(9):216-217.[12]陈镇新,薛青,纪君.尼莫同联合石杉碱甲治疗血管性痴呆的疗效观察[J].现代中西医结合杂志,2008,17(26):4072-4073.[13]闫凤霞,高维娟.血管性痴呆发病机制研究进展[J].承德医学院学报,2011,28(1):77-80.[14]杨申,崔瑞亭,刘运林.血管性痴呆的细胞学和分子机制研究进展[J].中华临床医师杂志(电子版),2016,(12):1785-1789.[15]Economos A,Wright CB,Moon YP,et al.Interleukin 6 plasma concentration associates with cognitive decline: the northern Manhattan study[J].Neuroepidemiology,2013,40(4):253-259.[16]Mulugeta E,Molina-Holgado F,Elliott MS,et al.Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia[J]. Dement Geriatr Cogn Disord,2008, 25(3): 278-286.[17]曹宇,裴卉,刘美霞,等.血管性痴呆的遗传学机制研究进展[J].中国临床神经科学,2017,25(5):586-594.[18]郭微,麦俊华,孙文强.中药有效成分石杉碱甲的多靶点作用研究进展[J].中国医药生物技术,2008,3(5):385-387.[19]李孟,张晓华.尼莫地平的药理作用及临床应用[J].吉林医学,2013(13):201-202.[20]韩威,姜慧轶,魏胜男,等.尼莫地平对局灶性脑缺血再灌注损伤大鼠脑神经元的保护作用及其机制[J].吉林大学学报(医学版),2014,40(3):598-601.[21]张丽欣,孙丽芳,刘毅,等.尼莫地平不同时间给药对血管性痴呆小鼠氧自由基代谢的影响[J].贵州医科大学学报,2017,42(3):305-307.

相似文献/References:

[1]彭莹萍.尼莫地平与盐酸氟桂利嗪治疗老年偏头痛的临床疗效观察[J].医学信息,2018,31(22):150.[doi:10.3969/j.issn.1006-1959.2018.22.044]
　PENG Ying-ping.Clinical Efficacy of Nimodipine and Flunarizine Hydrochloride in the Treatment of Senile Migraine[J].Medical Information,2018,31(11):150.[doi:10.3969/j.issn.1006-1959.2018.22.044]
[2]王芳芳,吴晓翠.尼莫地平对脑出血患者局部脑血流、脑水肿及不同时间用药临床变化的影响[J].医学信息,2019,32(05):158.[doi:10.3969/j.issn.1006-1959.2019.05.051]
　WANG Fang-fang,WU Xiao-cui.Effects of Nimodipine on Regional Cerebral Blood Flow,Brain Edema and Clinical Changes in Patients with Cerebral Hemorrhage[J].Medical Information,2019,32(11):158.[doi:10.3969/j.issn.1006-1959.2019.05.051]
[3]袁秀萍.高压氧联合尼莫地平治疗脑小血管病所致 认知功能障碍的疗效评价[J].医学信息,2019,32(17):79.[doi:10.3969/j.issn.1006-1959.2019.17.024]
　YUAN Xiu-ping.Efficacy Evaluation of Hyperbaric Oxygen Combined with Nimodipine in the Treatment of Cognitive Dysfunction Caused by Cerebral Small Vessel Disease[J].Medical Information,2019,32(11):79.[doi:10.3969/j.issn.1006-1959.2019.17.024]

更新日期/Last Update: 1900-01-01